市场见解

Are Nanosonics (ASX:NAN) shares a buy? Here’s what Motley Fool analyst Andrew Legget says

What’s the case for buying Nanosonics shares now?
The post Are Nanosonics (ASX:NAN) shares a buy? Here’s what Motley Fool analyst Andrew Legget says appeared first on The Motley Fool Australia. –

The Nanosonics Ltd (ASX: NAN) share price has failed to deliver a positive return for shareholders so far this year.

With hospitals inundated globally as a result of the COVID-19 pandemic, the infection technology company has struggled to promote its patented Trophon product. Despite this, the investing team at The Motley Fool Australia thinks there’s a lot to like about the business, making it a compelling opportunity.

In a discussion between Motley Fool Australia analyst Andrew Legget and our chief investment officer Scott Phillips, the COVID-19 headwind could be set to morph into a long-term tailwind for the infection technology company.

Let’s jump into the reasoning behind a positive outlook for Nanosonics shares on the ASX.

Renewed emphasis on sterilisation could help Nanosonics shares

While restrictions on surgical procedures may have impacted the performance of Nanosonics on the ASX in recent years, the outlook could be starting to shift. An indication of this is the company’s forecast for double-digit revenue growth in FY2022.

This increase would be from a higher number of installed devices and an uptick in consumables used across all regions — but where is this demand coming from?

Motley Fool analyst Andrew Legget recently offered an explanation, saying:

Hospitals have been busy, you’ve probably got all these COVID-related things to look after in the middle of a pandemic, the last thing you want to do is speak to a salesperson offering you an ultrasound disinfectant machine. But, I do expect that even the COVID pandemic will help in the long term because it did place a lot of focus on sterilisation.

A heightened focus on sterilisation might act as a catalyst to drive further Trophon sales. The major positive is that this phenomenon is global. Rather than one country seeing an increased need for disinfection protocols, it is essentially the entire world.

Attractive business model

In laying out the investment case for Nanosonics shares, Legget highlights the lucrative business model. It’s called the razor and blade model, and we’ve all likely fallen for it before. Legget explains:

You sell the device really cheap. Then once that device is installed and part of the process, then you open up the rivers of gold. Which are these consumable devices, which have extremely high margins. Every time you do a procedure that requires the usage of a Trophon device, you’re paying for a consumerable liquid that has really high margins.

Another bullish trait of the ASX-listed Nanosonics story is its position in the market. The company’s current installed base of devices is 26,760. However, management believes the market could be more than 100,000 machines.

On this note, Legget comments on the competition within the industry, saying:

I’ve had a look… it’s not easy to find competitors to what Nanosonics does. Also, the ones that you do find are not as complete a solution as what Nanosonics does. Nanonsonics, I said before, it is the gold standard.

In summary, Legget considers Nanosonics shares a beneficiary of increased importance on disinfection. The combination of its lucrative business model and lack of competition presents an opportunity for a very strong business.

The opinions expressed in this article were as at November 2021 and may change over time.

The post Are Nanosonics (ASX:NAN) shares a buy? Here’s what Motley Fool analyst Andrew Legget says appeared first on The Motley Fool Australia.

Should you invest $1,000 in Nanosonics right now?

Before you consider Nanosonics, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Nanosonics wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Nanosonics, WiseTech, and Zip shares are dropping

Nanosonics (ASX:NAN) share price tumbles despite guiding to strong growth at AGM

5 things to watch on the ASX 200 on Friday

10 top ASX shares to buy in November

Top ASX shares to buy in November 2021

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

随时随地,交易世界!

移动APP平台,拥有 12 个市场的 50,000 多种全球上市证券(全球市值超过 70%),直接在您的 Android 或 iOS 设备上即可操作。

与独有的交易理念和投资分析工具相结合,帮助您在我们 12 个全球市场中的几乎所有金融工具上找到可操作的见解,从而帮助您优化交易策略。

推荐给您的朋友

向您的朋友推荐Monex并赠予他们免费使用我们交易工具的机会

我们尊重您的隐私,只会向您的朋友发送一封邮件 

与您的朋友分享

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!